SCHEMBL2238376

SCHEMBL2238376

CN(C)c1ccc(OS(=O)(=O)c2cccc(NC(=O)NCCCl)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.59
MAPT P10636 3/20 0.59
KDM4E B2RXH2 1/20 0.52
CA12 O43570 5/20 0.46
CA1 P00915 5/20 0.46
CA2 P00918 5/20 0.46
CA9 Q16790 5/20 0.46
RAB9A P51151 3/20 0.45
NOX1 Q9Y5S8 3/20 0.45
NPC1 O15118 2/20 0.45
TP53 P04637 2/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
KMT2A Q03164 1/20 0.45
RELA Q04206 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2237861 0.88 MAPT (0.75) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL2234445 0.87 CA12 (0.56) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL2236488 0.87 MAPT (0.61) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL2236344 0.82 MAPT (0.56) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL13723591 0.81 SMN1; SMN2 (0.53) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL2237891 0.80 KDM4E (0.62) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL13826989 0.79 KDM4E (0.62) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL13723645 0.78 DHODH (0.61) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL13728203 0.77 MAPT (0.49) SMN1; SMN2MAPTKDM4ECA12CA1
SCHEMBL13724045 0.76 DHODH (0.49) SMN1; SMN2MAPTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2012142698-A1 ALKYLUREA DERIVATIVES ACTIVE AGAINST CANCER CELLS UNIVERSITE LAVAL (CA) 2012-10-26 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 SMN1; SMN2 2479/4885MAPT 4618/4885KDM4E 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.